KR20230120646A - 멀티시스트론성 rna 백신 및 이의 용도 - Google Patents
멀티시스트론성 rna 백신 및 이의 용도 Download PDFInfo
- Publication number
- KR20230120646A KR20230120646A KR1020237021041A KR20237021041A KR20230120646A KR 20230120646 A KR20230120646 A KR 20230120646A KR 1020237021041 A KR1020237021041 A KR 1020237021041A KR 20237021041 A KR20237021041 A KR 20237021041A KR 20230120646 A KR20230120646 A KR 20230120646A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleotide sequence
- sequence encoding
- operably linked
- antigen
- promoter
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700021021 mRNA Vaccine Proteins 0.000 title abstract description 9
- 229940022005 RNA vaccine Drugs 0.000 title abstract description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 1406
- 239000002773 nucleotide Substances 0.000 claims description 1395
- 239000000427 antigen Substances 0.000 claims description 897
- 102000036639 antigens Human genes 0.000 claims description 897
- 108091007433 antigens Proteins 0.000 claims description 897
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 643
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 473
- 230000001105 regulatory effect Effects 0.000 claims description 185
- 102000040430 polynucleotide Human genes 0.000 claims description 132
- 108091033319 polynucleotide Proteins 0.000 claims description 132
- 239000002157 polynucleotide Substances 0.000 claims description 132
- 108010006232 Neuraminidase Proteins 0.000 claims description 123
- 102000005348 Neuraminidase Human genes 0.000 claims description 123
- 108090000623 proteins and genes Proteins 0.000 claims description 85
- 108091035707 Consensus sequence Proteins 0.000 claims description 84
- 102000004169 proteins and genes Human genes 0.000 claims description 84
- 101710154606 Hemagglutinin Proteins 0.000 claims description 53
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 53
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 53
- 101710176177 Protein A56 Proteins 0.000 claims description 53
- 101710172711 Structural protein Proteins 0.000 claims description 43
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 42
- 108020004999 messenger RNA Proteins 0.000 claims description 41
- 102100031673 Corneodesmosin Human genes 0.000 claims description 25
- 102000011931 Nucleoproteins Human genes 0.000 claims description 23
- 108010061100 Nucleoproteins Proteins 0.000 claims description 23
- 101710139375 Corneodesmosin Proteins 0.000 claims description 22
- 241000700605 Viruses Species 0.000 claims description 22
- 241000710929 Alphavirus Species 0.000 claims description 19
- 239000000185 hemagglutinin Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 230000003612 virological effect Effects 0.000 claims description 17
- 241000712461 unidentified influenza virus Species 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 208000025721 COVID-19 Diseases 0.000 claims description 11
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 10
- 206010022000 influenza Diseases 0.000 claims description 10
- 206010062106 Respiratory tract infection viral Diseases 0.000 claims description 9
- 241001678559 COVID-19 virus Species 0.000 claims description 8
- 241000710960 Sindbis virus Species 0.000 claims description 8
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims description 8
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 241000124740 Bocaparvovirus Species 0.000 claims description 3
- 241000709661 Enterovirus Species 0.000 claims description 3
- 241000351643 Metapneumovirus Species 0.000 claims description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 3
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 3
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 241001493065 dsRNA viruses Species 0.000 claims description 3
- 241000701161 unidentified adenovirus Species 0.000 claims description 3
- 230000028996 humoral immune response Effects 0.000 claims description 2
- 230000002163 immunogen Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 241000711573 Coronaviridae Species 0.000 claims 2
- 206010011416 Croup infectious Diseases 0.000 claims 2
- 101710141454 Nucleoprotein Proteins 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 108020004511 Recombinant DNA Proteins 0.000 claims 2
- 201000010549 croup Diseases 0.000 claims 2
- 239000000839 emulsion Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 239000011859 microparticle Substances 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 230000003362 replicative effect Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101001024637 Severe acute respiratory syndrome coronavirus 2 Nucleoprotein Proteins 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940126582 mRNA vaccine Drugs 0.000 abstract description 4
- 229920002477 rna polymer Polymers 0.000 description 287
- 108010029566 avian influenza A virus hemagglutinin Proteins 0.000 description 118
- 108060003393 Granulin Proteins 0.000 description 86
- 230000000903 blocking effect Effects 0.000 description 54
- 150000003838 adenosines Chemical class 0.000 description 46
- 239000012634 fragment Substances 0.000 description 45
- 108020005345 3' Untranslated Regions Proteins 0.000 description 38
- 101710128560 Initiator protein NS1 Proteins 0.000 description 29
- 101710144127 Non-structural protein 1 Proteins 0.000 description 29
- 241000712431 Influenza A virus Species 0.000 description 28
- 108020003589 5' Untranslated Regions Proteins 0.000 description 24
- 230000035772 mutation Effects 0.000 description 16
- 241000004176 Alphacoronavirus Species 0.000 description 14
- 241000713196 Influenza B virus Species 0.000 description 13
- 101710138767 Non-structural glycoprotein 4 Proteins 0.000 description 13
- 102100031056 Serine protease 57 Human genes 0.000 description 13
- 101710197596 Serine protease 57 Proteins 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 9
- 108020005176 AU Rich Elements Proteins 0.000 description 8
- 102000004961 Furin Human genes 0.000 description 8
- 108090001126 Furin Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 235000013601 eggs Nutrition 0.000 description 6
- 230000008488 polyadenylation Effects 0.000 description 6
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 241000315672 SARS coronavirus Species 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 102200056390 rs12204826 Human genes 0.000 description 5
- GRYSXUXXBDSYRT-WOUKDFQISA-N (2r,3r,4r,5r)-2-(hydroxymethyl)-4-methoxy-5-[6-(methylamino)purin-9-yl]oxolan-3-ol Chemical group C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1OC GRYSXUXXBDSYRT-WOUKDFQISA-N 0.000 description 4
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 4
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 4
- 102220579649 ATP-dependent RNA helicase A_K417N_mutation Human genes 0.000 description 4
- 241000008904 Betacoronavirus Species 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 108010033040 Histones Proteins 0.000 description 4
- 108700011259 MicroRNAs Proteins 0.000 description 4
- 102220644248 Phosphoacetylglucosamine mutase_E484D_mutation Human genes 0.000 description 4
- 108091006197 SARS-CoV-2 Nucleocapsid Protein Proteins 0.000 description 4
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 208000037797 influenza A Diseases 0.000 description 4
- 239000002679 microRNA Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102220314004 rs1324631593 Human genes 0.000 description 4
- 102220237612 rs1554688023 Human genes 0.000 description 4
- RHFUOMFWUGWKKO-UHFFFAOYSA-N s2C Natural products S=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 RHFUOMFWUGWKKO-UHFFFAOYSA-N 0.000 description 4
- 241001461743 Deltacoronavirus Species 0.000 description 3
- 102220538701 Exosome complex exonuclease RRP44_Y489N_mutation Human genes 0.000 description 3
- 241000008920 Gammacoronavirus Species 0.000 description 3
- 244000309467 Human Coronavirus Species 0.000 description 3
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 3
- 102220599409 Spindlin-1_F490L_mutation Human genes 0.000 description 3
- 102220599652 Spindlin-1_F490S_mutation Human genes 0.000 description 3
- 102220599406 Spindlin-1_N501Y_mutation Human genes 0.000 description 3
- 102220355359 c.1522T>C Human genes 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- 102200002913 rs137854557 Human genes 0.000 description 3
- 102220040221 rs149738328 Human genes 0.000 description 3
- 102220277108 rs1553412687 Human genes 0.000 description 3
- UTAIYTHAJQNQDW-KQYNXXCUSA-N 1-methylguanosine Chemical compound C1=NC=2C(=O)N(C)C(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O UTAIYTHAJQNQDW-KQYNXXCUSA-N 0.000 description 2
- UVBYMVOUBXYSFV-UHFFFAOYSA-N 1-methylpseudouridine Natural products O=C1NC(=O)N(C)C=C1C1C(O)C(O)C(CO)O1 UVBYMVOUBXYSFV-UHFFFAOYSA-N 0.000 description 2
- JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 2
- BGTXMQUSDNMLDW-AEHJODJJSA-N 2-amino-9-[(2r,3s,4r,5r)-3-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@]1(O)F BGTXMQUSDNMLDW-AEHJODJJSA-N 0.000 description 2
- RHFUOMFWUGWKKO-XVFCMESISA-N 2-thiocytidine Chemical compound S=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RHFUOMFWUGWKKO-XVFCMESISA-N 0.000 description 2
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 2
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 2
- OGHAROSJZRTIOK-KQYNXXCUSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-O 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 2
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 101150077194 CAP1 gene Proteins 0.000 description 2
- 101150014715 CAP2 gene Proteins 0.000 description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102400000524 Fibrinogen alpha chain Human genes 0.000 description 2
- 101710137044 Fibrinogen alpha chain Proteins 0.000 description 2
- 102100028313 Fibrinogen beta chain Human genes 0.000 description 2
- 101710170765 Fibrinogen beta chain Proteins 0.000 description 2
- 108091081406 G-quadruplex Proteins 0.000 description 2
- 102000014702 Haptoglobin Human genes 0.000 description 2
- 108050005077 Haptoglobin Proteins 0.000 description 2
- 102100027772 Haptoglobin-related protein Human genes 0.000 description 2
- 101710122541 Haptoglobin-related protein Proteins 0.000 description 2
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 2
- 229930010555 Inosine Natural products 0.000 description 2
- 101710085938 Matrix protein Proteins 0.000 description 2
- 101710127721 Membrane protein Proteins 0.000 description 2
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 2
- 101100245221 Mus musculus Prss8 gene Proteins 0.000 description 2
- 101100260872 Mus musculus Tmprss4 gene Proteins 0.000 description 2
- NIDVTARKFBZMOT-PEBGCTIMSA-N N(4)-acetylcytidine Chemical compound O=C1N=C(NC(=O)C)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NIDVTARKFBZMOT-PEBGCTIMSA-N 0.000 description 2
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
- 102100022364 Polyunsaturated fatty acid 5-lipoxygenase Human genes 0.000 description 2
- 229930185560 Pseudouridine Natural products 0.000 description 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 102220599423 Spindlin-1_A475V_mutation Human genes 0.000 description 2
- 102220599672 Spindlin-1_D614G_mutation Human genes 0.000 description 2
- 102220590551 Spindlin-1_G339D_mutation Human genes 0.000 description 2
- 102220599654 Spindlin-1_G446S_mutation Human genes 0.000 description 2
- 102220599422 Spindlin-1_L452R_mutation Human genes 0.000 description 2
- 102220590546 Spindlin-1_N440K_mutation Human genes 0.000 description 2
- 102220592232 Spindlin-1_R346K_mutation Human genes 0.000 description 2
- 102220599655 Spindlin-1_S477N_mutation Human genes 0.000 description 2
- 102220599683 Spindlin-1_Y505H_mutation Human genes 0.000 description 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940029575 guanosine Drugs 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 229960003786 inosine Drugs 0.000 description 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 2
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 2
- 102220330701 rs1556000154 Human genes 0.000 description 2
- 102220114694 rs763810935 Human genes 0.000 description 2
- 102220077512 rs797044926 Human genes 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 229960004854 viral vaccine Drugs 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102100022712 Alpha-1-antitrypsin Human genes 0.000 description 1
- 241000004177 Alphacoronavirus 1 Species 0.000 description 1
- 241000008921 Avian coronavirus Species 0.000 description 1
- 241000008922 Beluga Whale coronavirus SW1 Species 0.000 description 1
- 241000008905 Betacoronavirus 1 Species 0.000 description 1
- 241000711443 Bovine coronavirus Species 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 101710118188 DNA-binding protein HU-alpha Proteins 0.000 description 1
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 1
- 241000283323 Delphinapterus leucas Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001123922 Hedgehog coronavirus 1 Species 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000823116 Homo sapiens Alpha-1-antitrypsin Proteins 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 101900156543 Influenza A virus Neuraminidase Proteins 0.000 description 1
- 241000008902 Miniopterus bat coronavirus 1 Species 0.000 description 1
- 241000008903 Miniopterus bat coronavirus HKU8 Species 0.000 description 1
- 241000008906 Murine coronavirus Species 0.000 description 1
- 101710144128 Non-structural protein 2 Proteins 0.000 description 1
- 101710199667 Nuclear export protein Proteins 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 241000008909 Pipistrellus bat coronavirus HKU5 Species 0.000 description 1
- 241001461748 Porcine coronavirus HKU15 Species 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000004178 Rhinolophus bat coronavirus HKU2 Species 0.000 description 1
- 241000008907 Rousettus bat coronavirus HKU9 Species 0.000 description 1
- 241000004179 Scotophilus bat coronavirus 512 Species 0.000 description 1
- 102220599680 Spindlin-1_A570D_mutation Human genes 0.000 description 1
- 102220592185 Spindlin-1_D215G_mutation Human genes 0.000 description 1
- 102220590324 Spindlin-1_D80A_mutation Human genes 0.000 description 1
- 102220599627 Spindlin-1_D950N_mutation Human genes 0.000 description 1
- 102220590604 Spindlin-1_K417N_mutation Human genes 0.000 description 1
- 102220590628 Spindlin-1_L18F_mutation Human genes 0.000 description 1
- 102220599660 Spindlin-1_T478K_mutation Human genes 0.000 description 1
- 102220590684 Spindlin-1_T95I_mutation Human genes 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102220510809 Toll-like receptor 3_P681H_mutation Human genes 0.000 description 1
- 241000008908 Tylonycteris bat coronavirus HKU4 Species 0.000 description 1
- 108700002693 Viral Replicase Complex Proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 108010091628 alpha 1-Antichymotrypsin Proteins 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 102220350121 c.1513T>C Human genes 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 108010059642 isinglass Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102220058585 rs137939966 Human genes 0.000 description 1
- 102220111603 rs147268052 Human genes 0.000 description 1
- 102220053106 rs199537178 Human genes 0.000 description 1
- 102220030033 rs398123766 Human genes 0.000 description 1
- 102220046286 rs587782805 Human genes 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063120362P | 2020-12-02 | 2020-12-02 | |
| US63/120,362 | 2020-12-02 | ||
| PCT/IB2021/061203 WO2022118226A1 (en) | 2020-12-02 | 2021-12-02 | Multicistronic rna vaccines and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230120646A true KR20230120646A (ko) | 2023-08-17 |
Family
ID=81852979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237021041A Pending KR20230120646A (ko) | 2020-12-02 | 2021-12-02 | 멀티시스트론성 rna 백신 및 이의 용도 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240024455A1 (https=) |
| EP (1) | EP4255446A4 (https=) |
| JP (1) | JP2023551982A (https=) |
| KR (1) | KR20230120646A (https=) |
| CN (1) | CN117222415A (https=) |
| AU (1) | AU2021392077A1 (https=) |
| CA (1) | CA3199996A1 (https=) |
| IL (1) | IL303315A (https=) |
| WO (1) | WO2022118226A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL296752A (en) * | 2020-04-03 | 2022-11-01 | Gritstone Bio Inc | Infectious disease antigens and vaccines |
| US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
| JP2025528112A (ja) * | 2022-08-08 | 2025-08-26 | セキラス インコーポレイテッド | Ｒｎａコードウイルス様粒子及びその使用 |
| TW202438672A (zh) * | 2023-01-31 | 2024-10-01 | 美商亞克圖羅斯醫療公司 | 四價流感疫苗之方法及組成物 |
| KR20250140103A (ko) * | 2023-02-09 | 2025-09-24 | 화이자 인코포레이티드 | 핵산 및 이의 용도 |
| AU2024271830A1 (en) * | 2023-05-12 | 2025-11-27 | Seqirus Inc. | Vaccine adjuvants |
| CN119101681A (zh) * | 2023-06-09 | 2024-12-10 | 仁景(苏州)生物科技有限公司 | 表达可调控的工程化rna分子 |
| EP4727580A1 (en) * | 2023-06-16 | 2026-04-22 | Seqirus Inc. | Virus-like particles for the treatment of sars-cov2 |
| WO2025003979A2 (en) * | 2023-06-30 | 2025-01-02 | Seqirus Inc. | Combination rna vaccine |
| CN121752291A (zh) * | 2023-06-30 | 2026-03-27 | 思齐乐私人有限公司 | SARS-CoV-2 RNA疫苗及其用途 |
| WO2025177220A1 (en) * | 2024-02-21 | 2025-08-28 | Seqirus Inc. | Alternative self-amplifying rna |
| WO2025217136A2 (en) * | 2024-04-08 | 2025-10-16 | Amplitude Therapeutics, Inc. | Trans-amplifying rnas encoding immunomodulators |
| WO2025215618A1 (en) * | 2024-04-12 | 2025-10-16 | Seqirus Inc. | Methods and reagents for treating or preventing ebv |
| WO2025230868A1 (en) * | 2024-04-29 | 2025-11-06 | Trustees Of Boston University | Self-amplifying rna and methods |
| WO2025257691A1 (en) * | 2024-06-10 | 2025-12-18 | Seqirus Inc. | Potency assay |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232324A1 (en) * | 2001-05-31 | 2003-12-18 | Chiron Corporation | Chimeric alphavirus replicon particles |
| EP2848692B1 (en) * | 2004-05-21 | 2017-08-16 | Novartis Vaccines and Diagnostics, Inc. | Alphavirus vectors for influenza virus vaccines |
| CA2766907A1 (en) * | 2009-07-06 | 2011-01-13 | Novartis Ag | Self replicating rna molecules and uses thereof |
| MX350258B (es) * | 2011-07-06 | 2017-08-31 | Novartis Ag | Emulsiones cationicas de aceite en agua. |
| RU2014118727A (ru) * | 2011-10-11 | 2015-11-20 | Новартис Аг | Рекомбинантные самореплицирующиеся полицистронные молекулы рнк |
| EP3015475A1 (en) * | 2014-10-31 | 2016-05-04 | Novartis AG | Mammalian cells expressing cytomegalovirus antigens |
| BE1024796B9 (fr) * | 2016-06-02 | 2019-01-08 | Glaxosmithkline Biologicals Sa | Constructions antigeniques du virus zika |
| WO2020028612A1 (en) * | 2018-08-01 | 2020-02-06 | Massachusetts Institute Of Technology | Rna-based regulatory technologies for mirna sensors |
| US12083174B2 (en) * | 2018-08-17 | 2024-09-10 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
-
2021
- 2021-12-02 KR KR1020237021041A patent/KR20230120646A/ko active Pending
- 2021-12-02 EP EP21900187.2A patent/EP4255446A4/en active Pending
- 2021-12-02 WO PCT/IB2021/061203 patent/WO2022118226A1/en not_active Ceased
- 2021-12-02 AU AU2021392077A patent/AU2021392077A1/en active Pending
- 2021-12-02 CA CA3199996A patent/CA3199996A1/en active Pending
- 2021-12-02 US US18/037,226 patent/US20240024455A1/en active Pending
- 2021-12-02 JP JP2023534301A patent/JP2023551982A/ja active Pending
- 2021-12-02 IL IL303315A patent/IL303315A/en unknown
- 2021-12-02 CN CN202180089244.XA patent/CN117222415A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023551982A (ja) | 2023-12-13 |
| AU2021392077A9 (en) | 2024-05-23 |
| EP4255446A4 (en) | 2025-05-14 |
| CN117222415A (zh) | 2023-12-12 |
| AU2021392077A1 (en) | 2023-07-13 |
| US20240024455A1 (en) | 2024-01-25 |
| CA3199996A1 (en) | 2022-06-09 |
| EP4255446A1 (en) | 2023-10-11 |
| WO2022118226A1 (en) | 2022-06-09 |
| IL303315A (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20230120646A (ko) | 멀티시스트론성 rna 백신 및 이의 용도 | |
| AU2020260491B2 (en) | Gene therapies for lysosomal disorders | |
| CN112226445B (zh) | 编码SARS-CoV-2病毒刺突蛋白的核酸及其的应用 | |
| AU2020205228B2 (en) | Gene therapies for lysosomal disorders | |
| KR20220141332A (ko) | 홍역-벡터화된 covid-19 면역원성 조성물 및 백신 | |
| AU2016353342B2 (en) | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies | |
| CA2776272C (en) | Development of a preventive vaccine for filovirus infection in primates | |
| CN114026115A (zh) | 用于溶酶体病症的基因疗法 | |
| CN116437968A (zh) | 用于神经退行性病症的基因疗法 | |
| CN114174324A (zh) | 用于溶酶体病症的基因疗法 | |
| KR20230051529A (ko) | 리소좀 장애에 대한 유전자 요법 | |
| RU2857683C2 (ru) | Мультицистронная самореплицирующаяся РНК для эффективной экспрессии более чем одного антигена, содержащая ее фармацевтическая композиция и способы применения | |
| US20230203536A1 (en) | Coronavirus rna replicons and use thereof as vaccines | |
| RU2855099C1 (ru) | Самореплицирующаяся РНК и ее применение | |
| KR20240139971A (ko) | 자가-복제 rna 및 이의 용도 | |
| HK40048832B (zh) | 用於溶酶体障碍的基因疗法 | |
| HK40046514A (en) | Gene therapies for lysosomal disorders | |
| HK40048832A (en) | Gene therapies for lysosomal disorders | |
| KR20210150487A (ko) | 리소좀 장애를 위한 유전자 요법 | |
| HK40067825A (zh) | 用於溶酶体障碍的基因疗法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230621 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20241128 Comment text: Request for Examination of Application |